The FDA granted an orphan drug designation to PEP-010 for the treatment of patients with metastatic pancreatic cancer.

ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

AccurEdit Therapeutics today announced that its innovative in vivo gene editing product, ART001, has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA).

Received a "Study May Proceed” letter from the FDA to evaluate amezalpat in combination with atezolizumab (TECENTRIQ®) and ...

Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin ...

Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant ...

has granted Orphan Drug Designation for RCT2100, a novel, investigational mRNA therapy being developed to treat cystic fibrosis (CF). CF is caused by mutations in the cystic fibrosis transmembrane ...

(RTTNews) - Palatin Technologies (PTN) announced the FDA has granted orphan drug designation to PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor deficiency ...

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025Alvelestat granted ...